Prevention of venous thromboembolism
78 results
1 - 78
Aspirin prevents recurrent venous thromboembolism- Enoxaparin better than aspirin for prevention of venous thromboembolism after total hip or knee arthroplasty
- Selective protocol for postpartum thromboprophylaxis is associated with a low rate of venous thromboembolism and few hematomas
- Rosuvastatin prevents DVT at very high cost
- LMWH better than unfractionated heparin for preventing DVT in medical patients
- Aspirin no different than rivaroxaban for prevention of VTE after TKA or THA
- Patients with initial unprovoked DVT or PE benefit from long-term low-dose aspirin (INSPIRE)
- Tinzaparin no better than warfarin in preventing recurrent VTE in adults with cancer
- Aspirin is no different than other anticoagulants for VTE prevention after joint replacement surgery
- Stockings plus anticoagulation more effective to prevent post-op VTE, but anticoagulation increases bleeding
- IPC safer and as effective as medical prophylaxis; much better than TEDS
- Direct oral anticoagulants are noninferior to low-molecular-weight heparin to prevent recurrent VTE in adults with cancer
- Aspirin following anticoagulation therapy prevents recurrent VTE (ASPIRE)
- Compression stockings unnecessary for inpatients who undergo elective surgery
- Dalteparin doesn't decrease pregnancy-related complications in women with thrombophilias (TIPPS)
- Abelacimab prevents asymptomatic clots better than enoxaparin, but there is no difference in clinical clots or major bleeding
- Thromboprophylaxis with apixaban prevents VTE in high-risk cancer patients (AVERT); jury still out on rivaroxaban (CASSINI)
- Aspirin alone may be sufficient protection from postop VTE after total knee arthroplasty
- 10 days enoxaparin better than 35 days rivaroxaban for medical inpatient thromboprophylaxis (MAGELLAN)
- Compression stockings ineffective after DVT
- Benefits/harms of novel oral anticoagulants similar in general population and the elderly
- Mobile compression device = LMWH for DVT prevention after hip replacement, less bleeding
- Low-intensity warfarin may be inferior to standard-intensity warfarin for preventing VTE after joint arthroplasty
- Lenalidomide effective for relapsed multiple myeloma
- Sulodexide given long-term may reduce recurrent VTE in patients with initial unprovoked VTE
- Oral rivaroxaban as effective as standard therapy for treatment of acute PE
- Semuloparin reduces VTE in cancer patients but at high cost (SAVE-ONCO)
- Greater benefit with rivaroxaban than aspirin for extended treatment of VTE
- Guidewire exchange of PICCs associated with higher risk of thrombosis
- Aspirin as safe and effective as LMWH for extended thromboprophylaxis after THA
- Guidelines for managing VTE (AAFP, ACP)
- Apixaban increases bleeding with no benefit in high-risk patients with ACS
- Slightly lower risk of major bleeds with apixaban (NNT = 83); no difference in efficacy
- Temporary IVC filter added to anticoagulation does not decrease risk of PE recurrence
- Top 10 strategies to improve patient safety
- Lasofoxifene has disease-specific benefits, but no change in all-cause mortality
- Low-dose rivaroxaban improves outcomes in patients with ACS (ATLAS)
- Extended follow-up: anastrozole better than placebo to prevent breast cancer in high-risk women (IBIS-II)
- Twice-daily low-dose aspirin is similar to enoxaparin for thromboprophylaxis after inpatient treatment for fracture (PREVENT CLOT)
- AHA/ACC guideline for the primary prevention of stroke
- Reduced-dose apixaban noninferior to full dose for cancer-associated VTE after 6 months, with less bleeding
- 2023 American Geriatric Society update on potentially inappropriate medication use in the elderly (Beers List)
- LMWH better than UFH for acute DVT